News >

Breast Oncologists Aim to Address Key Unanswered Questions With Novel Research Efforts

Kristi Rosa
Published: Tuesday, Feb 25, 2020

During the 2020 OncLive® State of the Science Summit on Breast Cancer, we asked experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.

 
Neelima Denduluri, MD, Associate Chair of Breast Medical Oncology and Medical Oncologist, Virginia Cancer Specialists, US Oncology Network

Neelima Denduluri, MD

Neelima Denduluri, MD: Associate Chair of Breast Medical Oncology and Medical Oncologist, Virginia Cancer Specialists, US Oncology Network

“One trial that we’re very excited about is speaking to the theme of hormone receptor (HR)–positive, HER2-negative early breast cancer. While we know that endocrine therapy certainly improves outcomes, as does chemotherapy in selected populations, we still have room to improve. CDK4/6 inhibitors have really moved the field forward in stage IV breast cancer, and we really need to see how that translates into the early breast cancer setting.

... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x